Loading
Almost every pancreatic cancer shares one of a handful of KRAS mutations. A pre-made vaccine against them could be given to every patient after surgery.
Almost every pancreatic cancer carries one of a handful of KRAS mutations, so this idea gives a pre-made KRAS vaccine to every patient after surgery, enriching for MRD-positive disease. Tumour burden is low after resection, the neoantigen is shared, ctDNA can enrich and monitor, and RAS inhibitors such as daraxonrasib may increase antigen presentation. ELI-002 7P from Elicio induced KRAS-specific T cells in phase 1 and is in the randomised AMPLIFY-7P phase 2, whereas personalised vaccines such as autogene cevumeran work but take weeks and cost more. The test is a phase 2/3 with ctDNA-positive enrichment and a recurrence-free survival endpoint. At early-clinical maturity it addresses the bottleneck The undruggable drivers.
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited trial reports Europe PMC returns for KRAS in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for KRAS in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for KRAS in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC).
Shares Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC), Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta, Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma, RASolute 302.
Shares RASolute 302, Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers.
Shares Off-the-shelf cancer vaccines, The undruggable drivers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, MRD / molecular residual disease testing.
Shares Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC), Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma, RASolute 302, Daraxonrasib.
Shares Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta, Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers.
Shares RASolute 302, Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers.
Shares Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers, KRAS.